Page 65 - Aet News Today

AstraZeneca starts the Cellectis partnership with $105 million in upfront cash and an equity investment. The pharmaceutical giant will also cover research costs for up to 10 cell therapy programs in oncology, immunology, and rare diseases.

MedCity News is inviting startups to apply for the INVEST 2024 Pitch Perfect Startup Contest on May 21-22 at the annual INVEST conference in the Ritz Carlton hotel in Chicago.

The vast majority of healthcare data isn't used because it's difficult to work with, according to Beth Andrews, chief digital health officer of life sciences and healthcare at Dell Technologies. Andrews made these comments during a session at the MedCity News INVEST Digital Health conference.

In an interview, Surescripts’ Clinical Product Advisor Cecelia Byers shared how the company is working to simplify prescribing and obtaining specialty medications.

Sarepta Therapeutics’ Duchenne muscular dystrophy gene therapy fell short of its main Phase 3 goal, but the firm contends the full body of evidence supports expanding the therapy’s label to all patients who have the muscle-wasting disease. Analysts say prospects of the therapy, Elevidys, rest on FDA willingness to exercise flexibility it has already shown to rare disease drugmakers, including Sarepta.

Several senators wrote a letter to the Biden Administration asking for action that ensures coverage of over-the-counter birth control without the need for a prescription. The letter was led by Senators Patty Murray (D-Washington), Tammy Baldwin (D-Wisconsin), Bernie Sanders (I-Vermont) and Ron Wyden (D-Oregon).

For the October episode, we discuss some recent executive hires and departures occurring in the healthcare sector, as well as layoffs affecting the industry. We also hear from Jeff Smith, who became the new CEO of Bamboo Health this month.

A drug development approach that makes use of hybrid AI can de-risk drug development while simultaneously removing other barriers to success. In other words, it has the power to significantly reduce the drug development timeline, and ultimately, save more lives.

In a fireside chat at INVEST Digital Health in Dallas, Polsinelli Healthcare M&A Co-chair Jonathan Henderson and Jim Walton, President of JWalton LLC discussed the healthcare preferences of different generations and how they will impact caregiving.

Gabby Everett, the site director for BioLabs Pegasus Park, offered a tour of the space and shared some examples of why early-stage life science companies should choose North Texas.